Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Accumulated Depreciation (2016 - 2021)

Historic Accumulated Depreciation for vTv Therapeutics (VTVT) over the last 8 years, with Q4 2021 value amounting to $305000.0.

  • vTv Therapeutics' Accumulated Depreciation rose 4120.37% to $305000.0 in Q4 2021 from the same period last year, while for Dec 2021 it was $305000.0, marking a year-over-year increase of 4120.37%. This contributed to the annual value of $305000.0 for FY2021, which is 4120.37% up from last year.
  • Latest data reveals that vTv Therapeutics reported Accumulated Depreciation of $305000.0 as of Q4 2021, which was up 4120.37% from $216000.0 recorded in Q4 2020.
  • In the past 5 years, vTv Therapeutics' Accumulated Depreciation registered a high of $9.1 million during Q4 2017, and its lowest value of $148000.0 during Q4 2019.
  • Over the past 5 years, vTv Therapeutics' median Accumulated Depreciation value was $305000.0 (recorded in 2021), while the average stood at $3.6 million.
  • In the last 5 years, vTv Therapeutics' Accumulated Depreciation crashed by 9824.46% in 2019 and then surged by 4594.59% in 2020.
  • Quarter analysis of 5 years shows vTv Therapeutics' Accumulated Depreciation stood at $9.1 million in 2017, then fell by 7.51% to $8.4 million in 2018, then plummeted by 98.24% to $148000.0 in 2019, then skyrocketed by 45.95% to $216000.0 in 2020, then soared by 41.2% to $305000.0 in 2021.
  • Its Accumulated Depreciation was $305000.0 in Q4 2021, compared to $216000.0 in Q4 2020 and $148000.0 in Q4 2019.